{"entity":{"id":"nct01497275","kind":"trial","name":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","aka":[],"tldr":"A phase 2 trial of Rituximab, Bortezomib and Ibritumomab tiuxetan in Mantle cell lymphoma, run by Duke University, recorded as terminated on the registry.","summary":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT01497275 by Duke University, with 5 participants recorded, started 2012-02 and due to reach its primary completion in 2014-05. Interventions recorded: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan. Conditions recorded: Mantle-Cell Lymphoma.\n\nLinked to the drug Ibritumomab tiuxetan because the registry names it among its interventions and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01497275","url":"https://clinicaltrials.gov/study/NCT01497275"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["rituximab","bortezomib","ibritumomab-tiuxetan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01497275","phase":"2","setting":"A Phase II Study Evaluating Combined Zevalin(Ibritumomab Tiuxetan)and Velcade(Bortezomib)in Relapsed/Refractory Mantle Cell Lymphoma","sponsor":"Duke University","started":"2012-02","yearReported":2015,"enrolled":5,"enrolledBasis":"registry","outcomes":[{"endpoint":"Response Rate (Complete Response + Partial Response)","primary":true,"unit":"participants","arms":[{"name":"Zevalin + Velcade","n":3,"value":0,"note":"Figures from the ClinicalTrials.gov results section (first posted 2015-06-04), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT01497275?tab=results"},{"endpoint":"Overall Survival at 1 Year","unit":"participants","arms":[{"name":"Zevalin + Velcade","n":4,"value":2,"note":"Figures from the ClinicalTrials.gov results section (first posted 2015-06-04), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT01497275?tab=results"},{"endpoint":"Number of Participants With Progression Free Survival","unit":"participants","arms":[{"name":"Zevalin + Velcade","n":3,"value":0,"note":"Figures from the ClinicalTrials.gov results section (first posted 2015-06-04), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT01497275?tab=results"}]},"route":"/trials/nct01497275/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"drug":[{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}]}}